SCHEMBL196024

SCHEMBL196024

Cc1cc(C)nc(C)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL6010194 0.96 POLB (0.50)
SCHEMBL3600351 0.79
SCHEMBL3096825 0.78
SCHEMBL3081567 0.78
SCHEMBL958039 0.78
SCHEMBL508369 0.78
SCHEMBL3096827 0.78
SCHEMBL6487423 0.78
SCHEMBL3083442 0.78
SCHEMBL786227 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1080 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066528-A1 Method for Synthesizing a Covalent Organic Framework Material YOCOF MAT SUZHOU CO LTD (CN) 2025-02-27 US claimed
CN-116903811-A Rank Kong Xiji covalent organic framework material and preparation method and application thereof 浙江大学杭州国际科创中心 2023-10-20 CN claimed
WO-2023124952-A1 GREEN SOLID-PHASE SYNTHESIS METHOD FOR COVALENT ORGANIC FRAMEWORK MATERIAL 张振杰 2023-07-06 WO claimed
EP-4151218-A1 LINAGLIPTIN, A XANTHINE DERIVATIVE AS DPP-4 INHIBITOR, FOR USE IN THE TREATMENT OF SIRS AND/OR SEPSIS Boehringer Ingelheim International GmbH (DE) 2023-03-22 EP claimed
EP-4104838-A1 Use of DPP IV inhibitors Boehringer Ingelheim International GmbH (DE) 2022-12-21 EP claimed
US-20220184088-A1 USES OF DPP IV INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2022-06-16 US claimed
EP-3939577-A1 PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE Boehringer Ingelheim International GmbH (DE) 2022-01-19 EP claimed
CN-110746471-B Preparation method of fondaparinux sodium disaccharide intermediate 江苏美迪克化学品有限公司 2021-06-25 CN claimed
US-20210093633-A1 TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY BOEHRINGER INGELHEIM INT (DE) 2021-04-01 US claimed
US-20200222411-A1 USES OF DPP IV INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2020-07-16 US claimed
US-7501426-B2 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-03-10 US claimed
WO-2009022007-A1 PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-02-19 WO claimed
WO-2009022010-A1 PHARMACEUTICAL COMPOSITION COMPRISING A SGLT2 INHIBITOR IN COMBINATION WITH A DPP-IV INHIBITOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-02-19 WO claimed
WO-2009022008-A1 PHARMACEUTICAL COMPOSITION COMPRISING A PYRAZOLE-O-GLUCOSIDE DERIVATIVE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-02-19 WO claimed
EP-2015754-A2 USES OF DPP-IV INHIBITORS Boehringer Ingelheim International GmbH (DE) 2009-01-21 EP claimed
WO-2008027479-A2 HIGHLY ACTIVE ALPHA-OLEFIN COPOLYMERIZATION CATALYST SYSTEM FORMOSA PLASTICS CORPORATION, U.S.A. (US) 2008-03-06 WO claimed
US-20080058198-A1 Highly active alpha-olefin copolymerization catalyst system FORMOSA PLASTICS CORPORATION, U.S.A. 2008-03-06 US claimed
US-20070281940-A1 USES OF DPP-IV INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-12-06 US claimed
WO-2007128761-A2 USES OF DPP-IV INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-11-15 WO claimed
US-20050234108-A1 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-10-20 US claimed